US President Donald Trump has threatened to impose tariffs of up to 200% on pharmaceuticals and 50% on copper imports from India. These proposed tariffs have raised concerns about their potential impact on India's pharmaceutical sector, which is a key supplier of generic drugs to the US market. Industry experts and former officials have noted that while copper exports might absorb the tariff impact, the pharmaceutical sector faces greater risks. Ravi Udaya Bhaskar, former Director General of Pharmexcil, emphasized that India is indispensable for US generic drug manufacturing and argued that the tariffs could ultimately hurt the US more than India. Experts also indicated that the 200% pharmaceutical tariffs might only be implemented by mid-to-late 2026, providing India with time to negotiate or seek phased rollouts. The tariff threats come amid broader trade tensions and have sparked discussions on India's response strategy, with calls to respond from a position of strength rather than acquiescing to the tariff threats. Additionally, former White House insiders have provided context on the broader implications of Trump's tariff plans for India and US-India relations.